A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Clinical trial NCT01028495 · COMPLETED

Trial details

NCT number: NCT01028495
Sponsor: Rexahn Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Pancreatic Cancer

Start date: 2009-05-01
Primary completion: 2012-07-01
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.